Provider review
Superior Remedies Review: A 68-Week Result Presented as Month Six
Superior Remedies does the thing this site keeps asking for: it names the trials behind its numbers. That is also what makes its errors visible. Its semaglutide page places "~15% average body weight reduction" at month 6, while STEP 1 — the trial it cites — measured −15.6% at week 68. The other family it cites, SUSTAIN, is the diabetes program rather than the obesity one.
Correction, August 2026
This review previously said: “Covered by the same single site-wide $149 figure; this program page publishes no price of its own.”
That was wrong. The figure on the home page carries no product name, and every program page publishes nothing, so this review treated the one visible number as the price of everything, on the microdose row as well as this one. It was never checked against the plan screen, because the plan screen only exists after the whole intake. One unattached price on a home page is not a price list, and reading it as one put a figure against a named company's tirzepatide product that the company does not charge for it.
It now says: Walked to the end of the eligibility quiz on 25 August 2026. Each product is priced separately on the plan screen that follows approval: semaglutide at the home page figure, tirzepatide two thirds higher, and the microdose program at the same figure as full-dose semaglutide, each against its own struck-through anchor. The billing cycle is 30 days by the terms, not a calendar month.
Superior Remedies is caught by its own honesty, which is an unusual way to be caught. It names STEP 1 and SUSTAIN as the source of its numbers, and naming them is what makes it checkable that one of the two is the diabetes program rather than the obesity one, and that the ~15% it places at month six was measured at week 68. The magnitudes are broadly right — ~15% for semaglutide and ~20% for tirzepatide are close to what the trials produced — so this is not a company inventing outcomes. It is a company describing real outcomes on a timeline the trials do not support, and borrowing half its authority from studies that were measuring blood sugar. Set against that: a microdose page that turns away the customers it could most easily sell to, a plain not-FDA-approved disclosure, and a refund term that means what it says. Read the numbers, ignore the calendar.
Worth trusting if
- You want a seller that names its trials, because it cites STEP 1 and SURMOUNT-1 by name and almost nobody in this market does.
- You are looking at the microdose program and want to be told when it is wrong for you, because its page turns away "patients with significant weight to lose".
- You live in California, Illinois, Michigan, New York, Utah, Virginia or Wisconsin, which is the list its own contact page gives.
Be skeptical if
- You need the price before you hand over your details, because no figure is attached to a product until the whole intake is done.
- You are planning around month six, because that is where both program pages put a result their own trials measured at week 68 and week 72.
- You want the cancellation rule in one place, because the terms say 48 hours' notice and the footer says 30 days'.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens superiorremedies.com. A link is not a recommendation to take anything.
Provenance
What Superior Remedies actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Semaglutide — GLP-1 Weight Loss program — $149 a cycle, and the cycle is 30 days rather than a calendar month by its own terms — "every 30 days thereafter until you cancel", which is 12.17 charges a year, or $1,813.33. Read 2026-08-10 that figure sat unattached on the home page and this note recorded it as the only price on the site. Re-checked 2026-08-25 by walking the eligibility quiz to the end: it is the semaglutide price specifically, shown against a struck-through $199, and it appears only after the whole intake is finished and an automated screen has said you are approved. The program page still carries no figure.
- Tirzepatide — Advanced Weight Loss program — Re-checked 2026-08-25, and this review previously had it wrong. Tirzepatide is not covered by the home page figure: the plan screen at the end of the eligibility quiz prices it at $249 a cycle against a struck-through $299, which is two thirds more than the semaglutide row. On the same 30-day cycle that is $3,030.33 a year. Nothing on the home page or the program page says so, and no figure for this product appears anywhere until the intake is complete.
- GLP-1 Microdose — Longevity & Composition — Re-checked 2026-08-25: the microdose program does have a price, and it is the same figure as the full-dose semaglutide program — the plan screen at the end of the quiz lists both at the same number, with no struck-through anchor on the microdose card. A lower dose of the same molecule for the same money is worth knowing before you pick it. The program page itself still publishes nothing.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Superior Remedies.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Superior Remedies’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Semaglutide — GLP-1 Weight Loss programSemaglutide · Compounded (503A)Claim reaches past the trials
“CLINICAL AVERAGE ~15% body weight. […] 03 MONTH 6 — ~15% Average body weight reduction reported in published trials. 04 YEAR 1+ Maintained — Most members sustain results with continued physician-directed treatment. […] Outcomes referenced from STEP 1 and SUSTAIN clinical trials.”
Read on the Superior Remedies site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry-verified 2026-08-11: primary outcome "Change in Body Weight (%)", timeframe "Baseline (week 0) to week 68", reported as −15.6% on semaglutide 2.4 mg against −2.8% on placebo. Week 68 is about 15.6 months — the trial Superior Remedies cites for a month-six figure.
- NCT02054897 SUSTAIN 1 — Phase 3, completed, n=388. Included to show what the second cited trial family actually studied: its registered condition is "Diabetes Mellitus, Type 2", as it is for every other SUSTAIN trial checked on 2026-08-11. The SUSTAIN program measured glycemic control in people with type 2 diabetes; weight change was a secondary matter and smaller than in STEP.
The magnitude is close and the timeline is not. STEP 1 produced −15.6%, and Superior Remedies says "~15%" — fair. But it places that figure at MONTH 6, and STEP 1 measured it at WEEK 68, which is about fifteen and a half months. A reader planning around this page expects in half a year what the trial took two and a half times as long to deliver. The citation is also half wrong: SUSTAIN is the type 2 diabetes program, with glycemic endpoints and a different population, so it cannot support a body-weight claim. And as everywhere in this category, STEP 1 tested Novo Nordisk's approved injectable; what is dispensed here is a compounded preparation with no registered trial of its own. None of that erases the credit for naming the trials at all — the error is visible only because the company showed its work.1
Tirzepatide — Advanced Weight Loss programTirzepatide · Compounded (503A)Claim reaches past the trials
“A dual-agonist GLP-1 / GIP program designed for patients seeking advanced metabolic results under provider direction with flat-rate pricing. CLINICAL AVERAGE ~20% body weight.”
Read on the Superior Remedies site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Registry-verified 2026-08-11: Completed, phase 3, 2,539 participants over 72 weeks, testing the approved injectable tirzepatide at a titrated therapeutic dose. Its top-dose result is close to the ~20% Superior Remedies quotes.
The magnitude is fair and the timeline is not, and this review previously graded it as a match because the timeline was not stated. Re-checked 2026-08-25, it is stated. The tirzepatide program page runs the same four-stage timeline as the semaglutide one and puts the number at stage three: "Month 6 ~20% Average body weight reduction in published trials. Many members exceed this range." SURMOUNT-1 ran 72 weeks, so month six is roughly a third of the way through the trial that produced the figure, and the same compression that makes the semaglutide claim overstate is now explicit here rather than latent. "Many members exceed this range" has nothing published behind it. The mechanism description — dual GLP-1/GIP agonist — is correct, the qualifier "Individual results vary. Ranges reflect clinical data for provider-supervised GLP-1 programs" is more than most of this category prints, and the trial tested the approved product rather than the compounded one sold.2
GLP-1 Microdose — Longevity & CompositionSemaglutide · Compounded (503A)No trial supports this claim
“A lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite regulation. […] ✕ CLINICAL EXCLUSION: Patients with significant weight to lose who would be better served by a standard GLP-1 protocol.”
Read on the Superior Remedies site, August 2026
No trial for this use
What the trials show for Semaglutide
The molecule has a large phase 3 program; this USE does not. ClinicalTrials.gov was searched on 2026-08-11 for completed interventional studies pairing semaglutide or tirzepatide with longevity, healthspan, aging or body-composition endpoints. One completed trial comes close and is worth naming rather than burying: NCT05786521, "Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults" — completed, phase 4, and it registers Aging itself as a condition, with lean body mass change from baseline to twenty weeks as its primary outcome. It is not a microdose trial, which is the whole point. Its published regimen titrates 0.25 mg weekly to 0.5 mg to 1.0 mg and holds there for twelve weeks — 1.0 mg is a standard maintenance dose, not a deliberately reduced one — and it enrolled twenty people, which is a pilot rather than a basis for a product claim. So the nearest registered evidence for "lower dose, different benefit" tested a normal dose in twenty patients. The remaining searches returned no completed trial of a sub-therapeutic regimen against these endpoints at all.
Selling a reduced dose for "metabolic health" and "body composition" asserts that less of the drug produces a different category of benefit, and no registered trial has tested that regimen for those endpoints. The appetite-regulation half is on firmer ground — appetite is what GLP-1 receptor agonists demonstrably act on — but the longevity-and-composition framing in the program's own name is not. One thing here deserves real credit and is rare enough to name: the page carries a CLINICAL EXCLUSION for "patients with significant weight to lose who would be better served by a standard GLP-1 protocol". Most microdose marketing in this category is aimed squarely at that customer. Turning them away, in writing, is the opposite of what this site usually finds.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. Superior Remedies describes itself as "a concierge telehealth platform that facilitates access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies", and adds that "the platform does not practice medicine, write prescriptions, or dispense pharmaceuticals" — a clearer statement of what it is than most of this market offers, attached to no pharmacy name, address or license number. Its footer states fulfillment is "Compounded in the USA". No compounding category appears: neither 503A nor 503B is mentioned.
Read on the Superior Remedies site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result or testing laboratory is published. The nearest statements are "Compounded in the USA" and the disclosure that compounded medications "are not FDA-approved and their safety, efficacy, and quality have not been independently verified by the FDA" — which is a candid admission rather than a quality claim, and is more than several companies we've reviewed manage. Re-checked 2026-08-25, there is now a testing claim as well, and it only appears inside the signup: the screen after approval says "Our state-licensed U.S. pharmacies run extra third-party testing on every compounded lot." No laboratory is named, no lot number is given, and no result is published, so there is nothing a reader can check. A claim to test every lot, made on a screen no one sees until they have finished the intake, is not the same as publishing a result.
Read on the Superior Remedies site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Re-checked 2026-08-25, and there is now a set to test the claim against — it disagrees with the claim. The badge strip says "TELEHEALTH IN ALL 50 STATES", the FAQ answer to "What states is this service available in?" says "Service is available across all 50 states", and the shipping-state dropdown inside the quiz lists all fifty plus the District of Columbia. The contact page says something else: "Superior Remedies operates telehealth across CA, IL, MI, NY, UT, VA, and WI." That is seven states. Both sentences are the company's own, published on the same site on the same day, and we cannot tell you which one is right. Ask before you pay if you live outside those seven.
Read the full licensing claim
"Independent, U.S. board-certified clinical providers", with the platform stating it does not itself practice medicine or write prescriptions. No individual clinician is named.
Read on the Superior Remedies site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Superior Remedies
We went through Superior Remedies’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Press "Check Eligibility · 2 min" on the home page.
- Four lifestyle screens first: what you want support with, how active you are, how much you sleep, how stressed you are.
- Say whether you are male or female.
- Enter height, current weight and goal weight. A BMI panel and a "success outlook" appear straight away.
- Give first name, last name, email and phone before any medical question is asked.
- Describe your body shape, then your ethnicity.
- Two checklists: everyday symptoms, then 15 medical exclusions from medullary thyroid cancer to gallbladder disease.
- Surgeries, then weight-loss surgeries specifically.
- A testimonial screen interrupts the questions, with a before-and-after photo and a "KEEP GOING" button.
- Prior GLP-1 use, current medications, two allergy screens, resting heart rate, how disruptive side effects would be.
- Date of birth, then a shipping address with a state dropdown listing all fifty states and the District of Columbia.
- Tick two consent boxes and press "SEE IF I QUALIFY". A loading screen says it is reviewing your answers, then returns "YOU'RE APPROVED".
- Only then does a plan screen name a price for each product. This walk stopped there, before any card details.
- One figure sits on the home page before the quiz — $149 a month, labeled a limited-time offer — and it is attached to no product. Which product it belongs to is only settled at the end.
- The plan screen after approval prices three products separately: semaglutide at $149, tirzepatide at $249, and the microdose program at the same figure as full-dose semaglutide. Only the first two carry a struck-through anchor.
- The terms charge "every 30 days thereafter until you cancel", not monthly, so 12.17 charges land in a year — $1,813.33 for semaglutide, $3,030.33 for tirzepatide. The plan screen also explains that a "month" is "one shot per week — four shots in total".
- "Cancel anytime" appears twice in the badge strip, and the site gives two different answers on how. The terms allow canceling "at any time up to forty-eight (48) hours before the applicable monthly processing date". The footer's refund policy says "Memberships may be canceled with 30 days' notice prior to the next billing cycle."
- The "success outlook" reads 92% no matter who is asking. We ran three profiles — BMI 31.2, 36.2 and 47.1 — and the number did not move. The weeks-to-goal beside it does move, which makes the fixed number easier to miss.
- "YOU'RE APPROVED" is issued by the page itself, seconds after the last question. The line under the plan cards says a licensed provider finalizes your plan before anything ships.
- The screen after approval claims "extra third-party testing on every compounded lot". No laboratory, lot number or result is published anywhere on the site.
Superior Remedies support
- Phone
- 510-631-0416
- Hours
- Monday to Friday, 9:00 AM to 5:00 PM MST (Arizona)
Assessment
What holds up, and what does not
- It names the trials behind its numbers — "Outcomes referenced from STEP 1 and SUSTAIN clinical trials" — which almost no one else in this market does.
- Its tirzepatide magnitude, ~20%, is a fair reading of SURMOUNT-1's top-dose result, and its mechanism description is correct.
- It publishes a clinic address, a phone number and clinical hours, which most of this market will not do.
Show 4 more
- Its microdose page excludes the very customers most microdose marketing targets: "patients with significant weight to lose who would be better served by a standard GLP-1 protocol".
- It prints the disclosure two companies in this market hold open FDA warning letters for omitting — compounded medications "are not FDA-approved and their safety, efficacy, and quality have not been independently verified by the FDA".
- It states plainly that it is a platform and does not practice medicine, write prescriptions or dispense pharmaceuticals.
- "$0 if you're not approved" is backed by a terms clause rather than left as a slogan.
- It places semaglutide's ~15% at MONTH 6. STEP 1 measured −15.6% at week 68 — about fifteen and a half months — so the timeline is compressed by a factor of roughly 2.6.
- Half its citation points at the wrong trial family: SUSTAIN is the type 2 diabetes program with glycemic endpoints, not the obesity program.
- Its microdose program is named for "Longevity & Composition" and no registered trial tests a sub-therapeutic GLP-1 regimen against either.
Show 8 more
- The tirzepatide page puts ~20% at month 6 as well, and SURMOUNT-1 ran 72 weeks — the same compression, stated rather than implied.
- Its own contact page says it operates telehealth in seven states while its badge strip and FAQ both say all fifty.
- The cancellation rule has two versions: 48 hours' notice in the terms, 30 days' notice in the footer's refund policy.
- The "success outlook" reads 92% for every profile we tried, across BMIs from 31.2 to 47.1.
- No price is attached to a named product until the intake is finished and the page has already told you that you are approved.
- Both trials cited tested approved products; what is dispensed is compounded and has no registered trial of its own.
- No pharmacy is named and no compounding category is stated.
- No certificate of analysis or testing result is published for any product.
Verdict
The bottom line
Take the magnitude and correct the calendar: about 15%, at roughly fifteen months rather than six. A company that cites its sources can be checked, which is why these two errors are worth more attention than a competitor’s uncited percentage — they are fixable, and they are still live.
Opens superiorremedies.com. A link is not a recommendation to take anything.
It names its trials, and that is why this review can be specific
"Outcomes referenced from STEP 1 and SUSTAIN clinical trials."
Almost nothing else reviewed on this site tells you where its numbers came from. Superior Remedies does — and everything below follows from that, because a company that cites nothing cannot be shown to have cited the wrong thing.
Full analysis — 5 more sectionsThe month-six problem · Half the citation is the wrong program · The microdose program, and the line it draws · What it costs, and when you find out · Two numbers the quiz hands back
The month-six problem
From its semaglutide program page:
"03 MONTH 6 ~15% Average body weight reduction reported in published trials."
STEP 1 (NCT03548935), registry-verified on 11 August 2026:
- Primary outcome — Change in Body Weight (%)
- Timeframe — Baseline (week 0) to week 68
- Result — −15.6% on semaglutide, −2.8% on placebo
Week 68 is about fifteen and a half months. The page presents that result as a month-six milestone, which compresses the trial's timeline by a factor of roughly 2.6.
The magnitude is honest. The calendar is not, and the calendar is what a patient plans around.
Half the citation is the wrong program
STEP is the obesity program. SUSTAIN is the type 2 diabetes program — checked against the registry, where SUSTAIN 1 (NCT02054897), SUSTAIN 4 (NCT02128932) and the rest all carry Diabetes Mellitus, Type 2 as their registered condition and glycemic endpoints as their primary outcomes.
Weight change in the SUSTAIN trials was a secondary observation in a different population being asked a different question. It cannot support a body-weight claim, and citing it alongside STEP lends the number authority it did not earn.
The microdose program, and the line it draws
The GLP-1 Microdose page sells "a lower-dose GLP-1 protocol designed for metabolic health, body composition, and appetite regulation". No registered trial tests a deliberately sub-therapeutic GLP-1 regimen against longevity, healthspan or body-composition endpoints — the STEP program titrated up to therapeutic doses and measured weight and cardiometabolic outcomes.
But the same page carries this:
"✕ CLINICAL EXCLUSION: Patients with significant weight to lose who would be better served by a standard GLP-1 protocol."
That is a company declining, in writing, to sell its longevity product to the customer with the biggest and most motivated problem. In this category that is genuinely rare, and it is worth putting next to the criticism above.
What it costs, and when you find out
Walked on 25 August 2026, with invented details and stopped before payment.
One figure is public before the quiz: $149 a month, on the home page, described as a limited-time offer and attached to no product. Every program page publishes nothing.
The eligibility quiz runs about thirty screens — four lifestyle questions, then your name, email and phone before a single medical question, then the medical checklists, then a date of birth and a full shipping address. Only after all of that, and after a screen that says "YOU'RE APPROVED", does a plan appear with a price against each product:
- Compounded Semaglutide Injection — $149 a month
- Compounded Tirzepatide Injection — $249 a month
- Compounded GLP-1 Microdose — the same figure as full-dose semaglutide
So the number on the home page is the semaglutide number. Tirzepatide is two thirds more, and nothing outside the quiz says so.
Then the cadence. The terms authorize a charge "immediately and every 30 days thereafter until you cancel", and the plan screen explains that a month means "one shot per week — four shots in total". Thirty-day cycles give 12.17 charges a year: $1,813.33 for semaglutide, $3,030.33 for tirzepatide.
And the cancellation rule has two versions on one site. The terms: cancel "at any time up to forty-eight (48) hours before the applicable monthly processing date". The footer's refund policy: "Memberships may be canceled with 30 days' notice prior to the next billing cycle." Both are the company's own words. Get the answer in writing before you start.
Two numbers the quiz hands back
The quiz prints a "success outlook" of 92% after it has your height and weight. We ran three profiles through it — BMI 31.2, 36.2 and 47.1 — and 92% did not move. The weeks-to-goal beside it did move, from 28 weeks to 43, which is what makes the fixed number easy to miss.
The final screen before consent shows a chart labeled "TYPICAL GLP-1 PROGRESS", −18% body weight, running week 0 to week 24. That is the month-six problem again, in a place the program pages do not reach: −18% is larger than STEP 1 reported at week 68, and week 24 is a third of the way there.
Questions
Frequently asked questions
Will I lose 15% of my body weight in six months?
Not on the evidence the page cites. Superior Remedies places "~15%" at month six, and STEP 1 — the trial it names — measured −15.6% at week 68, which is about fifteen and a half months. The magnitude is right and the timeline is compressed by roughly a factor of 2.6. Loss on these drugs is front-loaded, so month six is real progress; it is not, on this trial, the 15% figure.
Are STEP and SUSTAIN the same thing?
No, and the difference matters for a weight-loss claim. STEP is semaglutide's obesity program, and STEP 1 is where the ~15% comes from. SUSTAIN is its type 2 diabetes program — every SUSTAIN trial checked in the registry lists Diabetes Mellitus, Type 2 as its condition, with glycemic endpoints in a different population. Citing both as the source of a body-weight number means half the citation is answering a different question.
Is there evidence for GLP-1 microdosing for longevity or body composition?
No. No completed registered trial tests a sub-therapeutic GLP-1 regimen against longevity, healthspan or body-composition endpoints. The STEP program titrated up to full therapeutic doses and measured weight and cardiometabolic outcomes; it did not test a reduced dose and did not measure aging. Appetite regulation is on firmer ground — that is the mechanism these drugs demonstrably act through — but the "Longevity & Composition" framing in the program's own name is not supported. Credit where it is due: the same page refuses the customer most microdose marketing chases, excluding "patients with significant weight to lose".
Is Superior Remedies related to telos rx?
Not on anything either company publishes. telos rx's legal entity is Superior Health Solutions LLC and this one's is Superior Remedies LLC, each read off its own terms of service. They share a first word and nothing else that either site discloses — no common address, no shared operator statement, no cross-reference. A shared word is not evidence of a relationship, and none is asserted here.
Glossary
Key terms
Show definitions
- STEP program
- Semaglutide's phase 3 trial program in overweight and obesity, measuring percentage change in body weight. STEP 1 enrolled 1,961 adults and reported −15.6% at week 68.
- SUSTAIN program
- Semaglutide's phase 3 trial program in type 2 diabetes, measuring glycemic control. A different population and different endpoints from STEP; weight change appears as a secondary observation.
- Timeline compression
- Quoting a trial's endpoint result against a shorter period than the trial ran. The number is real and the schedule is not, which matters because a patient decides whether treatment is working against the schedule they were given.
Compare
Others selling what Superior Remedies sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Superior Remedies's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.